Breaking News Instant updates and real-time market news.

ASMB

Assembly Biosciences

$41.85

-2.2 (-4.99%)

07:11
07/25/18
07/25
07:11
07/25/18
07:11

Assembly Biosciences receives fast track designation for ABI-H0731 for HepB

Assembly Biosciences announced that the U.S. Food and Drug Administration has granted Fast Track designation to ABI-H0731 for the treatment of patients with chronic Hepatitis B infection. ABI-H0731 is Assembly's lead oral HBV core inhibitor, which is being evaluated in two global Phase 2a proof of concept studies that are currently enrolling patients. The Fast Track program is intended to facilitate the development and review of drug candidates that treat serious conditions and fill an unmet medical need. A drug candidate with Fast Track designation is eligible for greater access to the FDA for the purpose of expediting the drug product candidate's development, review and potential approval. Assembly recently initiated two multi-center, randomized, placebo controlled Phase 2a trials of ABI-H0731, which are actively recruiting and dosing subjects at multiple locations in the U.S. and globally. The ABI-H0731-201 "viral antigen trial" is enrolling HBeAg positive HBV patients whose viral load has already been suppressed on a standard of care nucleos(t)ide therapy. Patients will be randomized to receive either daily ABI-H0731 or placebo in addition to their continued nucleos(t)ide therapy for six months. The viral antigen trial will compare declines in HBV S antigen and HBV E antigen as well as safety and tolerability of the combination therapy to that of patients on standard-of-care nucleos(t)ide therapy alone. In the ABI-H0731-202 "viral load trial," HBeAg positive HBV patients are being enrolled who are naive to nucleos(t)ide treatment and will be randomized to receive either daily ABI-H0731 or placebo in combination with entecavir for six months. The viral load trial will assess the antiviral potency as measured by viral DNA suppression as well as safety and tolerability of the combination compared with entecavir alone. Initial results from both studies are anticipated in the first half of 2019.

ASMB Assembly Biosciences
$41.85

-2.2 (-4.99%)

03/08/18
JEFF
03/08/18
NO CHANGE
Target $75
JEFF
Buy
Assembly Biosciences price target raised to $75 from $50 at Jefferies
Jefferies analyst Michael Yee raised his price target for Assembly Biosciences to $75 and keeps a Buy rating on the shares. The analyst continues to like Assembly as a top smid-cap biotech idea given "emerging promising data" for core protein inhibitors in Hepatitis B, its "own strong and growing" pipeline with data catalysts this year, and "significant" market opportunity. Further, the analyst sees the company's $120M cash position as sufficient to move beyond 2018 and fund large Phase II studies.
04/12/18
JEFF
04/12/18
NO CHANGE
Target $75
JEFF
Buy
New data from Assembly Biosciences look 'great,' says Jefferies
Assembly Biosciences presented this morning positive detailed results from its Phase IB study of oral ABI-H0731 in chronic hepatitis B patients, Jefferies analyst Michael Yee tells investors in a research note titled "New EASL Data Looks Great - Potent Efficacy Across HBV Populations - BUY." He believes the data show potent efficacy and dose response across hepatitis B patients as well as clean safety and tolerability. The analyst thinks Assembly "will increasingly be getting on the map" of big pharma and large biotech. The company remains an attractive takeover candidate for big companies in the anti-viral space as its drugs are "starting to play out," Yee contends. He keeps a Buy rating on Assembly Biosciences with a $75 price target.
04/13/18
CHDN
04/13/18
DOWNGRADE
CHDN
Neutral
Assembly Biosciences downgraded to Neutral from Buy at Chardan
04/13/18
WBLR
04/13/18
NO CHANGE
WBLR
Outperform
Assembly Biosciences fair value estimate raised to $84 from $52 at William Blair
William Blair analyst Y. Katherine Xu raised her fair value estimate of Assembly Biosciences shares to $84 from $52 after the company presented interim Phase Ib data for candidate ABI-H0731. The potency seen so far with ABI-H0731 represents the best-in-class among the congenital pulmonary airway malformation candidates in the clinic, Xu tells investors in a research note. The analyst increased the probability of success for Assembly's CpAM class to become a component of some future hepatitis B virus curing regimens to 40% from 20%. The analyst keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

ATEX

Anterix

$46.95

-0.66 (-1.39%)

21:10
07/16/19
07/16
21:10
07/16/19
21:10
Syndicate
Anterix 2.22M share Secondary priced at $45.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 17

    Jul

TNXP

Tonix Pharmaceuticals

$0.57

-0.4087 (-41.75%)

21:08
07/16/19
07/16
21:08
07/16/19
21:08
Syndicate
Tonix Pharmaceuticals 9M share Secondary priced at $0.60 »

Aegis is acting as sole…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Jul

HTHT

Huazhu Group

$34.88

0.23 (0.66%)

21:05
07/16/19
07/16
21:05
07/16/19
21:05
Earnings
Huazhu Group sees Q2 revenue growth of 13%-15% »

Reports Q2 blended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PS

Pluralsight

$30.66

-0.71 (-2.26%)

20:58
07/16/19
07/16
20:58
07/16/19
20:58
Initiation
Pluralsight initiated at KeyBanc »

Pluralsight initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

TWOU

2U

$38.60

-0.34 (-0.87%)

20:57
07/16/19
07/16
20:57
07/16/19
20:57
Initiation
2U initiated at KeyBanc »

2U initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BVN

Buenaventura

$16.31

-0.03 (-0.18%)

20:36
07/16/19
07/16
20:36
07/16/19
20:36
Hot Stocks
Buenaventura reports Q2 Orcopampa gold production 10.7K oz vs. 5.9K in Q1 »

The company also lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

HOPE

Hope Bancorp

$13.96

0.2 (1.45%)

20:33
07/16/19
07/16
20:33
07/16/19
20:33
Hot Stocks
Hope Bancorp authorizes $50M stock repurchase program »

Hope Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

20:25
07/16/19
07/16
20:25
07/16/19
20:25
Conference/Events
CLSA Asian tech analyst team to hold an analyst/industry conference call »

Asian Technology Analysts…

BAC

Bank of America

$28.99

-0.23 (-0.79%)

, ABT

Abbott

$83.11

-0.69 (-0.82%)

20:25
07/16/19
07/16
20:25
07/16/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$28.99

-0.23 (-0.79%)

ABT

Abbott

$83.11

-0.69 (-0.82%)

USB

U.S. Bancorp

$53.04

-0.07 (-0.13%)

PNC

PNC Financial

$138.66

-1.52 (-1.08%)

PGR

Progressive

$84.11

0.105 (0.12%)

BK

BNY Mellon

$43.13

-0.02 (-0.05%)

OMC

Omnicom

$84.08

0.065 (0.08%)

TXT

Textron

$54.02

0.59 (1.10%)

CMA

Comerica

$71.75

0.39 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 26

    Aug

  • 06

    Sep

  • 16

    Oct

SCGLY

Societe Generale

$0.00

(0.00%)

20:08
07/16/19
07/16
20:08
07/16/19
20:08
Upgrade
Societe Generale rating change at JPMorgan »

Societe Generale upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$299.75

-1.03 (-0.34%)

, SPX

S&P 500

$0.00

(0.00%)

20:06
07/16/19
07/16
20:06
07/16/19
20:06
Periodicals
SF Fed President Daly not leaning in either direction on rates, Reuters says »

In a Reuters interview,…

SPY

SPDR S&P 500 ETF Trust

$299.75

-1.03 (-0.34%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAFD

Washington Federal

$34.63

0.02 (0.06%)

20:02
07/16/19
07/16
20:02
07/16/19
20:02
Earnings
Washington Federal reports Q3 EPS 67c, consensus 64c »

Reports Q3 NII $121.7M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$44.72

0.755 (1.72%)

19:16
07/16/19
07/16
19:16
07/16/19
19:16
Initiation
PagSeguro Digital initiated at Evercore ISI »

PagSeguro Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

, CTAS

Cintas

$239.46

-3.85 (-1.58%)

18:50
07/16/19
07/16
18:50
07/16/19
18:50
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

CTAS

Cintas

$239.46

-3.85 (-1.58%)

UAL

United Continental

$94.00

2.7 (2.96%)

QCOM

Qualcomm

$75.66

0.23 (0.30%)

NUS

Nu Skin

$45.50

1.44 (3.27%)

SENS

Senseonics

$1.68

-0.075 (-4.29%)

CSX

CSX

$79.57

1.05 (1.34%)

IBKR

Interactive Brokers

$50.72

-0.44 (-0.86%)

INO

Inovio

$3.00

0.05 (1.69%)

TELL

Tellurian

$7.68

-0.1 (-1.29%)

WB

Weibo

$41.57

-1.47 (-3.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

  • 31

    Jul

  • 06

    Aug

  • 07

    Aug

  • 26

    Aug

  • 09

    Sep

  • 13

    Nov

  • 18

    Jul

NVLN

Novelion Therapeutics

$0.71

-0.0054 (-0.75%)

18:46
07/16/19
07/16
18:46
07/16/19
18:46
Hot Stocks
Novelion Therapeutics announces BC Court dismissed action filed by Whitefort »

Novelion Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLGNF

Dialog Semiconductor

$0.00

(0.00%)

18:41
07/16/19
07/16
18:41
07/16/19
18:41
Earnings
Dialog Semiconductor raises Q2 revenue view to $482M »

Prior view was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHP

BHP Group

$57.59

-0.27 (-0.47%)

18:39
07/16/19
07/16
18:39
07/16/19
18:39
Hot Stocks
BHP Group reports Q4 iron ore output 63MT, down 2% from last year »

Reports FY19 iron ore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

DPZ

Domino's Pizza

$246.55

-23.42 (-8.68%)

18:33
07/16/19
07/16
18:33
07/16/19
18:33
Hot Stocks
Domino's Pizza CEO: We are in a position of strength »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 13

    Nov

UBER

Uber

$44.13

-0.38 (-0.85%)

18:18
07/16/19
07/16
18:18
07/16/19
18:18
Periodicals
Uber rolls out ride-hailing services in Hamburg, Germany, Reuters says »

Uber said it is rolling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

LFUS

Littelfuse

$168.35

-2.05 (-1.20%)

18:03
07/16/19
07/16
18:03
07/16/19
18:03
Earnings
Littelfuse reports preliminary Q2 EPS $1.91, consensus $2.03 »

Reports preliminary Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 19

    Sep

S

Sprint

$7.23

0.12 (1.69%)

, SSNLF

Samsung

$0.00

(0.00%)

17:51
07/16/19
07/16
17:51
07/16/19
17:51
Periodicals
Sprint says hackers broke into user accounts via Samsung site, ZDNet says »

Sprint (S) informed…

S

Sprint

$7.23

0.12 (1.69%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

17:50
07/16/19
07/16
17:50
07/16/19
17:50
Hot Stocks
Seattle Genetics up 8% to $68.20 after Q2 results »

The company achieved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 09

    Sep

QCOM

Qualcomm

$75.66

0.23 (0.30%)

17:48
07/16/19
07/16
17:48
07/16/19
17:48
Periodicals
DOJ requests halt of antitrust ruling against Qualcomm, Reuters reports »

The U.S. Justice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MFGP

Micro Focus

$20.66

-0.01 (-0.05%)

17:46
07/16/19
07/16
17:46
07/16/19
17:46
Downgrade
Micro Focus rating change at Goldman Sachs »

Micro Focus downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$132.39

-1.12 (-0.84%)

17:45
07/16/19
07/16
17:45
07/16/19
17:45
Hot Stocks
SPDR Gold Shares holdings fall from 800.54MT to 799.37MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.